About Gossamer Bio
Gossamer Bio is a company based in San Diego (United States) founded in 2017 by Faheem Hasnain.. Gossamer Bio has raised $330 million across 4 funding rounds from investors including Arch Venture Partners, Monashee Investment Management and EcoR1. The company has 145 employees as of December 31, 2024. Gossamer Bio has completed 1 acquisition, including Respira Therapeutics. Gossamer Bio offers products and services including Seralutinib. Gossamer Bio operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter San Diego, United States
- Employees 145 as on 31 Dec, 2024
- Founders Faheem Hasnain
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Gossamer Bio, Inc.
-
Annual Revenue
$114.7 M0as on Dec 31, 2024
-
Net Profit
$-56.53 M68.56as on Dec 31, 2024
-
EBITDA
$-55.77 M67.07as on Dec 31, 2024
-
Total Equity Funding
$330 M (USD)
in 4 rounds
-
Latest Funding Round
$212.1 M (USD), Post-IPO
Jul 20, 2023
-
Investors
Arch Venture Partners
& 11 more
-
Employee Count
145
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Gossamer Bio
Gossamer Bio is a publicly listed company on the NASDAQ with ticker symbol GOSS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Gossamer Bio
Gossamer Bio offers a comprehensive portfolio of products and services, including Seralutinib. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhaled inhibitor for treating pulmonary hypertension diseases.
Unlock access to complete
Unlock access to complete
Funding Insights of Gossamer Bio
Gossamer Bio has successfully raised a total of $330M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $212.1 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $212.1M
-
First Round
First Round
(04 Jan 2018)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2023 | Amount | Post-IPO - Gossamer Bio | Valuation |
investors |
|
| Jul, 2022 | Amount | Post-IPO - Gossamer Bio | Valuation |
investors |
|
| Jul, 2018 | Amount | Series B - Gossamer Bio | Valuation | Hillhouse |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Gossamer Bio
Gossamer Bio has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Arch Venture Partners, Monashee Investment Management and EcoR1. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Gossamer Bio
Gossamer Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Respira Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics to treat Pulmonary Arterial Hypertension using proprietary drug delivery technology.
|
2010 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Gossamer Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Gossamer Bio Comparisons
Competitors of Gossamer Bio
Gossamer Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for allergic and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Gossamer Bio
Frequently Asked Questions about Gossamer Bio
When was Gossamer Bio founded?
Gossamer Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is Gossamer Bio located?
Gossamer Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Gossamer Bio?
Faheem Hasnain is the current CEO of Gossamer Bio. They have also founded this company.
Is Gossamer Bio a funded company?
Gossamer Bio is a funded company, having raised a total of $330M across 4 funding rounds to date. The company's 1st funding round was a Series B of $230M, raised on Jan 04, 2018.
How many employees does Gossamer Bio have?
As of Dec 31, 2024, the latest employee count at Gossamer Bio is 145.
What is the annual revenue of Gossamer Bio?
Annual revenue of Gossamer Bio is $114.7M as on Dec 31, 2024.
What does Gossamer Bio do?
Gossamer Bio was founded in 2017 and is headquartered in San Diego, United States. Operations focus on the biotechnology sector, where small molecule-based therapies are developed to address immunological disorders, inflammation, and cancer. Drug candidates include GB001, targeted at inflammatory disorders with an undisclosed mechanism, and first-in-class HIF-1α stabilizers designed for inflammatory bowel diseases.
Who are the top competitors of Gossamer Bio?
Gossamer Bio's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
What products or services does Gossamer Bio offer?
Gossamer Bio offers Seralutinib.
Is Gossamer Bio publicly traded?
Yes, Gossamer Bio is publicly traded on NASDAQ under the ticker symbol GOSS.
How many acquisitions has Gossamer Bio made?
Gossamer Bio has made 1 acquisition, including Respira Therapeutics.
Who are Gossamer Bio's investors?
Gossamer Bio has 12 investors. Key investors include Arch Venture Partners, Monashee Investment Management, EcoR1, NEA, and Weiss Asset Management.
What is Gossamer Bio's ticker symbol?
The ticker symbol of Gossamer Bio is GOSS on NASDAQ.